AdaptHealth vs Bruker
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put AdaptHealth and Bruker side by side, using each one’s latest annual report. Here is what stands out:
- Bruker is the larger business, with $3.4B of revenue in fiscal 2025 against $3.2B for AdaptHealth.
- Bruker grew revenue faster (2.1%, against −0.5%).
- AdaptHealth kept more of each dollar of sales as operating profit (2.8% operating margin, against 2.0%).
- AdaptHealth turned more of its sales into free cash flow (6.8% FCF margin, against 1.3%).
- AdaptHealth earned a higher return on the capital invested in it (2.1%, against 0.9%).
Who comes out ahead
Of the 11 measures where higher (or lower) is clearly better, how many each company leads.
AdaptHealth
AHCO
6/11
5-year growthOperating marginFCF marginReturn on capitalNet debt / EBITDAShare count change
Bruker
BRKR
4/11
Revenue growthGross marginNet marginReturn on equity
Side by side
Best in the row
| Latest fiscal year | AHCO FY25 | BRKR FY25 |
|---|---|---|
| Size | ||
| Market cap | $807M | $8.9B |
| Revenue | $3.2B | $3.4B |
| Free cash flow | $219M | $43.3M |
| Net income | −$70.8M | −$8.6M |
| Growth | ||
| Revenue growth | −0.5% | 2.1% |
| 5-year growth | 25.2% | 11.6% |
| Share count change | −0.3% | 1.5% |
| Profitability | ||
| Gross margin | 18.8% | 45.9% |
| Operating margin | 2.8% | 2.0% |
| Net margin | −2.2% | −0.3% |
| FCF margin | 6.8% | 1.3% |
| Return on capital | 2.1% | 0.9% |
| Return on equity | −4.6% | −0.4% |
| Balance sheet | ||
| Net debt | $1.7B | $1.6B |
| Net debt / EBITDA | 3.6x | 5.5x |
| Dividends and buybacks | $0.0M | $32.8M |
| Valuation & quality | ||
| P/E | — | — |
| Piotroski F-score | 4 | 4 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.